[e-farmacos] Cerivastatina y farmacovigilancia en JAMA

["Canas, Martin" <macanas@netverk.com.ar>]

Estimadas y estimados, 

Para leer y analizar.

El JAMA publica en forma adelantada online una serie de articulos que evaluan los datos referentes a las reacciones adversas la cerivastatina, retirada en el 2001, los conflictos de interes y sobre la vigilancia poscomercializacion.

Los articulos seran publicados en el numero del 1 de dicembre, e incluyen entre otros a autores como Psaty, Rennie, DeAngelis y Brian Strom.

Los articulos y sus correspondientes hipervinculos son:

David J. Graham, MD, MPH; Judy A. Staffa, PhD; Deborah Shatin, PhD; Susan E. Andrade, ScD; Stephanie D. Schech, MPH; Lois La Grenade, MD, MPH; Jerry H. Gurwitz, MD; K. Arnold Chan, MD, ScD; Michael J. Goodman, PhD; Richard Platt, MD, MSc  
Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering Drugs JAMA. 2004;292:(DOI 10.1001/jama.292.21.2585). 
http://jama.ama-assn.org/cgi/content/full/292.21.2585v1

Bruce M. Psaty, MD, PhD; Curt D. Furberg, MD, PhD; Wayne A. Ray, PhD; Noel S. Weiss, MD, DrPH. Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions. Use of Cerivastatin and Risk of Rhabdomyolysis .JAMA. 2004;292:(DOI 10.1001/jama.292.21.2622). 
http://jama.ama-assn.org/cgi/content/full/292.21.2622v1

Joseph D. Piorkowski, Jr, DO, JD, MPH. Bayer's Response to "Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis" JAMA. 2004;292:(DOI 10.1001/jama.292.21.2655). 
http://jama.ama-assn.org/cgi/content/full/292.21.2655v1

Bruce M. Psaty, MD, PhD; Curt D. Furberg, MD, PhD; Wayne A. Ray, PhD; Noel S. Weiss, MD, DrPH. Authors' Reply to Bayer's Response to "Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis" JAMA. 2004;292:(DOI 10.1001/jama.292.21.2658). 
http://jama.ama-assn.org/cgi/content/full/292.21.2658v1

Brian L. Strom, MD, MPH. Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions A Counterpoint  JAMA. 2004;292:(DOI 10.1001/jama.292.21.2643).
http://jama.ama-assn.org/cgi/content/full/292.21.2643v1

Phil B. Fontanarosa, MD; Drummond Rennie, MD; Catherine D. DeAngelis, MD, MPH. Postmarketing Surveillance-Lack of Vigilance, Lack of Trust JAMA. 2004;292:(DOI 10.1001/jama.292.21.2647). 
http://jama.ama-assn.org/cgi/content/full/292.21.2647v1

Saludos,

Martin

Martin Canas
GAPURMED
La Plata  (Argentina)
macanas@netverk.com.ar